Developer docs
API playgroundTry for free, no card

Search company profiles

Outlook Therapeutics

Full company profile

uuid0000r7y

Namestring
Outlook Therapeutics
Legal namestring
Outlook Therapeutics, Inc.
Company typeenum
Public
Founded yearint
2015
Descriptiontext

Outlook Therapeutics (NASDAQ: OTLK) is a biopharmaceutical company developing and commercializing a single ophthalmic asset — ONS-5010/LYTENAVA (bevacizumab-vikg in the US; bevacizumab gamma in the EU/UK) — an ophthalmic formulation of the recombinant humanized anti-VEGF monoclonal antibody bevacizumab, delivered via intravitreal injection for the treatment of retinal diseases. The product targets wet age-related macular degeneration (wet AMD) as its lead indication, with diabetic macular edema (DME) and branch retinal vein occlusion (BRVO) as subsequent label-expansion opportunities; LYTENAVA's value proposition rests on being the first ophthalmic-specific bevacizumab formulation, addressing contamination, potency variability, and supply disruptions associated with compounded IV bevacizumab. Manufacturing is centralized with proprietary process controls for sterility, pH, and particulate limits meeting ophthalmic regulatory standards.

The company operates a specialty-pharma commercial model using a direct enterprise field sales force in Europe (deployed through specialty distributors in Germany, UK, and Austria) and a channel-led US go-to-market pending FDA approval — including specialty distribution via Cencora and McKesson, GPO partnerships (SPN, CureScript, OnMark), and a patient services hub. The drug was authorized by the European Commission (May 2024) and UK MHRA (July 2024) with a positive NICE recommendation (December 2024), and commercial launches occurred in Germany and the UK in June 2025 and Austria in 2026. The US BLA has been resubmitted (June 2026) with a PDUFA target action date of July 29, 2026, following a successful FDA Formal Dispute Resolution appeal in May 2026.

Financials reflect a pre-scale single-asset biotech: ~17 employees, FY2025 product revenue of $1.4M from initial European launches, FY2025 net loss of $62.4M (improved from $75.4M), and a series of debt and equity financings in 2025-2026 (Atlas Sciences $18.4M note; multiple H.C. Wainwright-led public and registered direct offerings and an Avondale Capital convertible note) to sustain operations through anticipated US commercialization.

Short descriptiontext

Outlook Therapeutics is a biopharmaceutical company developing and commercializing ONS-5010/LYTENAVA, the first ophthalmic-specific formulation of bevacizumab, for the intravitreal treatment of retinal diseases — primarily wet AMD — serving retina specialists and ophthalmologists across the EU, UK, and pending US markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersIselin, United States
HQ citystring
Iselin
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ophthalmic pharmaceuticals, anti-VEGF therapy, bevacizumab formulation, retinal disease treatment, biopharmaceutical products
Industry1 code
PRIMARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Ophthalmic Biopharmaceuticals
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Product Sales (LYTENAVA)
TypeOne Time License
Description

Revenue from commercial sales of LYTENAVA (bevacizumab gamma) for wet AMD in European markets. Initial product revenue began June 2025 in Germany and UK, expanded to Austria in 2026. Q2 FY2026 showed approximately 10% sequential decline in European unit sales. Swiss market launch expected in 2027 pending regulatory approval through Mediconsult distribution agreement.

globenewswire.com
2US Market (Pending FDA Approval)
TypeOne Time License
Description

If FDA approves ONS-5010/LYTENAVA, the company expects to generate US product revenue through specialty distribution channels, GPO contracts, and direct provider engagement. PDUFA target action date set for July 29, 2026.

globenewswire.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
Pricing details1 tier
1Pricing not publicly disclosed
ModelOtherBilling cadencePay-as-you-go
Notes

Pricing details for LYTENAVA are not publicly disclosed. In the US market (pending approval), the product would be reimbursed under Medicare Part B through buy-and-bill model.

outlooktherapeutics.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1LYTENAVA
Description

ONS-5010/LYTENAVA is an ophthalmic formulation of bevacizumab (bevacizumab-vikg in the US, bevacizumab gamma in EU/UK) for the treatment of wet age-related macular degeneration (wet AMD). It is a recombinant humanized monoclonal antibody that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF's biologic activity.

outlooktherapeutics.com
Core offering1 text field

Outlook Therapeutics develops and commercializes ONS-5010/LYTENAVA (bevacizumab-vikg in the US; bevacizumab gamma in the EU/UK), an ophthalmic formulation of the anti-VEGF monoclonal antibody bevacizumab, administered via intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). The product has received European Commission and MHRA Marketing Authorization and is under FDA review in the United States.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Outlook Therapeutics is a biopharmaceutical company with a single focused product: ONS-5010/LYTENAVA (bevacizumab-vikg in the US; bevacizumab gamma in the EU/UK). This is an ophthalmic formulation of the anti-VEGF monoclonal antibody bevacizumab, positioned to become the first approved ophthalmic formulation of bevacizumab for retinal disease indications. The product is administered via intravitreal injection and targets VEGF to reduce endothelial cell proliferation, vascular leakage, and new blood vessel formation in the retina. The company operates with a single-product portfolio: ONS-5010/LYTENAVA is approved and commercially launched in Europe (Germany, Austria) and the UK, while the US BLA remains under FDA review with a PDUFA target action date of July 29, 2026.

Product and service1 record
1ONS-5010 / LYTENAVA (bevacizumab-vikg / bevacizumab gamma)
CategoryOphthalmic Biopharmaceutical
Description

Ophthalmic formulation of bevacizumab (a recombinant humanized anti-VEGF monoclonal antibody) administered via intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD), with additional indications under development for diabetic macular edema (DME) and branch retinal vein occlusion (BRVO). Approved in EU and UK; under FDA review in the United States.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Mediconsult AG
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-19
Description

Exclusive commercial distribution agreement with Mediconsult AG for Switzerland market. Mediconsult holds exclusive rights to market, import, distribute, and commercialize LYTENAVA (bevacizumab gamma) for wet AMD treatment in Switzerland. Mediconsult is responsible for regulatory activities including seeking Marketing Authorization in Switzerland. Outlook Therapeutics retains manufacturing, product supply, and intellectual property responsibilities. Expected Swiss market launch in 2027 pending regulatory approval.

stocktitan.net
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Regeneron markets Eylea (aflibercept), the leading FDA-approved anti-VEGF therapy for wet AMD. As the dominant premium anti-VEGF product targeting the same wet AMD patient population, it is the most direct competitor Outlook would face on US launch of LYTENAVA.

TypeBroad incumbent
Description

Bausch + Lomb is a diversified ophthalmology company with a broad portfolio in retinal therapeutics, eye drops, surgical, and vision care products. It operates in the same ophthalmology commercial channel as Outlook Therapeutics.

TypeDirect peer
Description

Through its acquisition of Iveric Bio, Astellas markets Izervay (avacincaptad pegol) for geographic atrophy and competes in the retinal disease space with similar specialty/retina-focused commercialization.

TypeBroad incumbent
Description

Alcon is a global ophthalmology leader with surgical, vision care, and pharmaceutical offerings. While not a direct anti-VEGF competitor, it operates in the same ophthalmology prescribers, payers, and distribution channels.

TypeBroad incumbent
Description

Amgen markets Mvasi, a bevacizumab biosimilar approved for oncology indications. Its commercial bevacizumab biosimilar infrastructure represents a potential competitive or partnering reference point for Outlook's ophthalmic bevacizumab strategy.

TypeDirect peer
Description

Genentech markets Lucentis (ranibizumab) for wet AMD and is the originator of Avastin (bevacizumab), the IV product currently compounded off-label for ophthalmology use — the exact practice Outlook's LYTENAVA seeks to convert to an FDA-approved ophthalmic bevacizumab.

TypeDirect peer
Description

Apellis markets Syfovre and Aspaveli, retinal therapeutics targeting wet AMD/geographic atrophy. As a focused retina biopharma with similar patient and HCP targets to Outlook, Apellis is a relevant direct peer in commercial-stage retinal disease.

TypeDirect peer
Description

Novartis markets Beovu (brolucizumab), another FDA-approved anti-VEGF therapy for wet AMD, directly competing with ONS-5010/LYTENAVA in the same intravitreal anti-VEGF category.

TypeEmerging player
Description

Samsung Bioepis develops biosimilars including bevacizumab (referenced as SB8/Aybintio). As a bevacizumab biosimilar developer, it is thematically comparable to Outlook's biosimilar/originator-bevacizumab positioning in retinal disease.

TypeEmerging player
Description

Kodiak Sciences is developing next-generation anti-VEGF therapies (KSI-301 / tarcocimab) for retinal diseases including wet AMD. It targets the same wet AMD patient population with a differentiated sustained-release approach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds18 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors18 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Outlook Therapeutics

Ophthalmic Biopharmaceuticalsoutlooktherapeutics.com

Outlook Therapeutics is a biopharmaceutical company developing and commercializing ONS-5010/LYTENAVA, the first ophthalmic-specific formulation of bevacizumab, for the intravitreal treatment of retinal diseases — primarily wet AMD — serving retina specialists and ophthalmologists across the EU, UK, and pending US markets.

What Outlook Therapeutics does

Outlook Therapeutics (NASDAQ: OTLK) is a biopharmaceutical company developing and commercializing a single ophthalmic asset — ONS-5010/LYTENAVA (bevacizumab-vikg in the US; bevacizumab gamma in the EU/UK) — an ophthalmic formulation of the recombinant humanized anti-VEGF monoclonal antibody bevacizumab, delivered via intravitreal injection for the treatment of retinal diseases. The product targets wet age-related macular degeneration (wet AMD) as its lead indication, with diabetic macular edema (DME) and branch retinal vein occlusion (BRVO) as subsequent label-expansion opportunities; LYTENAVA's value proposition rests on being the first ophthalmic-specific bevacizumab formulation, addressing contamination, potency variability, and supply disruptions associated with compounded IV bevacizumab. Manufacturing is centralized with proprietary process controls for sterility, pH, and particulate limits meeting ophthalmic regulatory standards.

The company operates a specialty-pharma commercial model using a direct enterprise field sales force in Europe (deployed through specialty distributors in Germany, UK, and Austria) and a channel-led US go-to-market pending FDA approval — including specialty distribution via Cencora and McKesson, GPO partnerships (SPN, CureScript, OnMark), and a patient services hub. The drug was authorized by the European Commission (May 2024) and UK MHRA (July 2024) with a positive NICE recommendation (December 2024), and commercial launches occurred in Germany and the UK in June 2025 and Austria in 2026. The US BLA has been resubmitted (June 2026) with a PDUFA target action date of July 29, 2026, following a successful FDA Formal Dispute Resolution appeal in May 2026.

Financials reflect a pre-scale single-asset biotech: ~17 employees, FY2025 product revenue of $1.4M from initial European launches, FY2025 net loss of $62.4M (improved from $75.4M), and a series of debt and equity financings in 2025-2026 (Atlas Sciences $18.4M note; multiple H.C. Wainwright-led public and registered direct offerings and an Avondale Capital convertible note) to sustain operations through anticipated US commercialization.

Outlook Therapeutics firmographics

Firmographics
Name
Outlook Therapeutics
Legal name
Outlook Therapeutics, Inc.
Website
https://outlooktherapeutics.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
51–100 employees
Short description
Outlook Therapeutics is a biopharmaceutical company developing and commercializing ONS-5010/LYTENAVA, the first ophthalmic-specific formulation of bevacizumab, for the intravitreal treatment of retinal diseases — primarily wet AMD — serving retina specialists and ophthalmologists across the EU, UK, and pending US markets.
Ownership category
akta.pro rank

Outlook Therapeutics industry classification

Industry
Product category
Ophthalmic Biopharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals

Keywords

  • Ophthalmic pharmaceuticals
  • Anti-VEGF therapy
  • Bevacizumab formulation
  • Retinal disease treatment
  • Biopharmaceutical products

Where Outlook Therapeutics is headquartered

Location

Headquarters

HQ city
Iselin
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Outlook Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

  1. Product Sales (LYTENAVA): Revenue from commercial sales of LYTENAVA (bevacizumab gamma) for wet AMD in European markets. Initial product revenue began June 2025 in Germany and UK, expanded to Austria in 2026. Q2 FY2026 showed approximately 10% sequential decline in European unit sales. Swiss market launch expected in 2027 pending regulatory approval through Mediconsult distribution agreement.
  2. US Market (Pending FDA Approval): If FDA approves ONS-5010/LYTENAVA, the company expects to generate US product revenue through specialty distribution channels, GPO contracts, and direct provider engagement. PDUFA target action date set for July 29, 2026.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goPricing not publicly disclosed

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Outlook Therapeutics product offering

Product offering

Core offering

Outlook Therapeutics develops and commercializes ONS-5010/LYTENAVA (bevacizumab-vikg in the US; bevacizumab gamma in the EU/UK), an ophthalmic formulation of the anti-VEGF monoclonal antibody bevacizumab, administered via intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). The product has received European Commission and MHRA Marketing Authorization and is under FDA review in the United States.

Product overview

Outlook Therapeutics is a biopharmaceutical company with a single focused product: ONS-5010/LYTENAVA (bevacizumab-vikg in the US; bevacizumab gamma in the EU/UK). This is an ophthalmic formulation of the anti-VEGF monoclonal antibody bevacizumab, positioned to become the first approved ophthalmic formulation of bevacizumab for retinal disease indications. The product is administered via intravitreal injection and targets VEGF to reduce endothelial cell proliferation, vascular leakage, and new blood vessel formation in the retina. The company operates with a single-product portfolio: ONS-5010/LYTENAVA is approved and commercially launched in Europe (Germany, Austria) and the UK, while the US BLA remains under FDA review with a PDUFA target action date of July 29, 2026.

Differentiator

Problem solved

Functional benefit

Brands

  • LYTENAVA: ONS-5010/LYTENAVA is an ophthalmic formulation of bevacizumab (bevacizumab-vikg in the US, bevacizumab gamma in EU/UK) for the treatment of wet age-related macular degeneration (wet AMD). It is a recombinant humanized monoclonal antibody that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF's biologic activity.

Products and services

  • ONS-5010 / LYTENAVA (bevacizumab-vikg / bevacizumab gamma) Ophthalmic formulation of bevacizumab (a recombinant humanized anti-VEGF monoclonal antibody) administered via intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD), with additional indications under development for diabetic macular edema (DME) and branch retinal vein occlusion (BRVO). Approved in EU and UK; under FDA review in the United States.

Companies that use Outlook Therapeutics

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Outlook Therapeutics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Outlook Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Mediconsult AGcoreChannel Partner/ Reseller/ Distributor · 19 February 2026Exclusive commercial distribution agreement with Mediconsult AG for Switzerland market. Mediconsult holds exclusive rights to market, import, distribute, and commercialize LYTENAVA (bevacizumab gamma) for wet AMD treatment in Switzerland. Mediconsult is responsible for regulatory activities including seeking Marketing Authorization in Switzerland. Outlook Therapeutics retains manufacturing, product supply, and intellectual property responsibilities. Expected Swiss market launch in 2027 pending regulatory approval.

Scale indicators12 records

Recent moves6 records

Expansion highlights5 records

Outlook Therapeutics competitors and assessment

Company assessment

Direct peers

  • Regeneron Pharmaceuticals: Regeneron markets Eylea (aflibercept), the leading FDA-approved anti-VEGF therapy for wet AMD. As the dominant premium anti-VEGF product targeting the same wet AMD patient population, it is the most direct competitor Outlook would face on US launch of LYTENAVA.
  • Astellas Pharma (Iveric Bio): Through its acquisition of Iveric Bio, Astellas markets Izervay (avacincaptad pegol) for geographic atrophy and competes in the retinal disease space with similar specialty/retina-focused commercialization.
  • Genentech (Roche): Genentech markets Lucentis (ranibizumab) for wet AMD and is the originator of Avastin (bevacizumab), the IV product currently compounded off-label for ophthalmology use — the exact practice Outlook's LYTENAVA seeks to convert to an FDA-approved ophthalmic bevacizumab.
  • Apellis Pharmaceuticals: Apellis markets Syfovre and Aspaveli, retinal therapeutics targeting wet AMD/geographic atrophy. As a focused retina biopharma with similar patient and HCP targets to Outlook, Apellis is a relevant direct peer in commercial-stage retinal disease.
  • Novartis: Novartis markets Beovu (brolucizumab), another FDA-approved anti-VEGF therapy for wet AMD, directly competing with ONS-5010/LYTENAVA in the same intravitreal anti-VEGF category.

Broad incumbents

  • Bausch + Lomb: Bausch + Lomb is a diversified ophthalmology company with a broad portfolio in retinal therapeutics, eye drops, surgical, and vision care products. It operates in the same ophthalmology commercial channel as Outlook Therapeutics.
  • Alcon: Alcon is a global ophthalmology leader with surgical, vision care, and pharmaceutical offerings. While not a direct anti-VEGF competitor, it operates in the same ophthalmology prescribers, payers, and distribution channels.
  • Amgen: Amgen markets Mvasi, a bevacizumab biosimilar approved for oncology indications. Its commercial bevacizumab biosimilar infrastructure represents a potential competitive or partnering reference point for Outlook's ophthalmic bevacizumab strategy.

Emerging players

  • Samsung Bioepis: Samsung Bioepis develops biosimilars including bevacizumab (referenced as SB8/Aybintio). As a bevacizumab biosimilar developer, it is thematically comparable to Outlook's biosimilar/originator-bevacizumab positioning in retinal disease.
  • Kodiak Sciences: Kodiak Sciences is developing next-generation anti-VEGF therapies (KSI-301 / tarcocimab) for retinal diseases including wet AMD. It targets the same wet AMD patient population with a differentiated sustained-release approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

Outlook Therapeutics social profiles

Digital presence

Outlook Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Outlook Therapeutics leadership team

Management profile

Number of profiles

Profiles9 records

Outlook Therapeutics funding detail

Funding detail

Funding overview

Funding rounds18 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Outlook Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Outlook Therapeutics

What does Outlook Therapeutics do?

Outlook Therapeutics develops and commercializes ONS-5010/LYTENAVA (bevacizumab-vikg in the US; bevacizumab gamma in the EU/UK), an ophthalmic formulation of the anti-VEGF monoclonal antibody bevacizumab, administered via intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). The product has received European Commission and MHRA Marketing Authorization and is under FDA review in the United States.

Is Outlook Therapeutics a public or private company?

Outlook Therapeutics is a public company. It is classified as public and is currently operating.

When was Outlook Therapeutics founded?

Outlook Therapeutics was founded in 2015. It employs 51 to 100 people.

Where is Outlook Therapeutics based?

Outlook Therapeutics is headquartered in Iselin, United States, in the North America region.

How does Outlook Therapeutics make money?

Two revenue lines are on record. Product Sales (LYTENAVA) is the primary driver. The others are US Market (Pending FDA Approval).

Who are Outlook Therapeutics's main competitors?

Direct peers on record are Regeneron Pharmaceuticals, Astellas Pharma (Iveric Bio), Genentech (Roche), Apellis Pharmaceuticals and Novartis. Broad incumbents are Bausch + Lomb, Alcon and Amgen. Emerging players are Samsung Bioepis and Kodiak Sciences.

Does Outlook Therapeutics have an API?

No public API is recorded for Outlook Therapeutics.

What industry is Outlook Therapeutics in?

Outlook Therapeutics's product category is Ophthalmic Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Simply Wall StOutlook Therapeutics (OTLK) Stock Looks Hard To Judge On Book ValueOutlook Therapeutics' share price has fallen 98.4% over five years, and its P/B ratio is -9.4x, indicating negative shareholder equity. The negative ratio means book value does not anchor valuation, so investors must assess the pipeline, funding needs, and dilution risk.Simply Wall StWhen Will Outlook Therapeutics, Inc. (NASDAQ:OTLK) Turn A Profit?Outlook Therapeutics, a clinical-stage biopharmaceutical company, narrowed its full-year loss to $61M from $62M, approaching breakeven. Analysts expect the company to incur a final loss in 2027 and generate $21M in profit in 2028, requiring average 56% annual growth.citybizOutlook Therapeutics Names Greg DiPasquale Chief Commercial Officer Ahead of LYTENAVA U.S. LaunchOutlook Therapeutics appointed Greg DiPasquale as Chief Commercial Officer ahead of its U.S. launch of LYTENAVA, an FDA-approved bevacizumab for wet AMD. The company targets availability for eligible U.S. patients before the end of 2026. DiPasquale will oversee sales, marketing, and market access.Stock TitanOutlook Therapeutics Names Greg DiPasquale CCOOutlook Therapeutics named Greg DiPasquale Chief Commercial Officer to lead U.S. commercialization of LYTENAVA, an FDA-approved wet AMD treatment. The company plans to make the drug available to eligible U.S. patients before the end of 2026. DiPasquale brings over 30 years of commercial leadership experience in eye care.Stock TitanOutlook Therapeutics Seeks CMS J-Code for LYTENAVAOutlook Therapeutics submitted an application to CMS for a permanent J-code for LYTENAVA, the only FDA-approved ophthalmic bevacizumab for wet AMD. The company remains on track for a U.S. commercial launch before the end of 2026, though the application does not guarantee coverage or reimbursement.BioSpaceOutlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)Outlook Therapeutics submitted an application to CMS for a permanent, product-specific HCPCS Level II J-code for LYTENAVA, its ophthalmic bevacizumab for wet AMD. The company remains on track for a U.S. commercial launch before the end of 2026. The submission does not guarantee CMS will assign the code or that coverage will be granted.Investing.comOutlook Therapeutics at H.C. Wainwright: launch hinges on access By Investing.comOutlook Therapeutics announced FDA approval of LYTENAVA, its first ophthalmic bevacizumab for wet AMD, at the H.C. Wainwright conference. The company plans a focused launch targeting practices dissatisfied with repackaged bevacizumab, pricing under $500 per dose, and expects a permanent J-code in April 2027 to drive broader adoption.Investing.comOutlook Therapeutics at H.C. Wainwright: launch hinges on access By Investing.comOutlook Therapeutics outlined its commercial launch of FDA-approved LYTENAVA for wet AMD at the H.C. Wainwright conference, targeting practices dissatisfied with repackaged bevacizumab. The company aims to price under $500 per dose and expects a permanent J-code in April 2027 to drive broader adoption. Analysts project a stock price range of $1.60 to $10.50.Investing.comOutlook Therapeutics at H.C. Wainwright: launch hinges on access By Investing.comOutlook Therapeutics outlined its commercial launch of FDA-approved LYTENAVA for wet AMD at the H.C. Wainwright conference, targeting a market of 2.2 million repackaged bevacizumab injections annually. The company plans pricing under $500 per dose and a permanent J-code in April 2027, while facing reimbursement delays and a market cap of $161 million.Stock TitanOutlook Therapeutics H.C. Wainwright Chat On-DemandOutlook Therapeutics made its H.C. Wainwright conference fireside chat available on-demand, featuring CEO Bob Jahr and analyst Douglas Tsao. Management will meet registered investors on-site in New York during the conference September 14-16, 2026.